OpportunityTitle: Innovation in Development and Qualification of Alternative Testing Methodologies for Reproductive Toxicology (U01)
AdditionalInformationOnEligibility: PLEASE Note:  The entities eligible to enter into partnerships with FDA are governed by Section 566 of the FD&amp;C Act [21 U.S.C. 360bbb-5].    An eligible organization that wishes to enter into a collaborative agreement must provide an assurance that the entity will not accept funding for a Crtical Path Public-Private Partnership Project from any organization that manufactures or distributes products regulated by the Food and Drug Administration (FDA)unless the entity provides assurances in its agreement with FDA that the results of the Critical Path Public-Private Partnership Project will not be influenced by any source of funding.
Description: As part of Food and Drug Administration&apos;s Advancing Regulatory Science initiative the Office of Critical Path Programs (OCPP) supports innovation to improve the development and evaluation of new safe and effective medical products for diagnosing, treating, and preventing conditions and diseases. OCPP is working to harness new science and new technologies to further this goal.This Funding Opportunity Announcement (FOA) will provide resources for research into the development and qualification of alternative methodologies in the area of reproductive toxicology, which have the potential to be more predictive than the currently required testing, and which will reduce, refine, or replace animal testing.Applications should address the Critical Path Initiative&apos;s mission to facilitate the development of new safe and effective products for diagnosing, treating, and preventing disease.
GrantorContactEmailDescription: FDA office e-mail
GrantorContactText: Gladys M. Bohler &lt;br/&gt;Grants Management Officer/Specialist &lt;br/&gt;Phone 301-827-7175